Search

Your search keyword '"Chang Wook, Kim"' showing total 55 results

Search Constraints

Start Over You searched for: Author "Chang Wook, Kim" Remove constraint Author: "Chang Wook, Kim" Topic gastroenterology Remove constraint Topic: gastroenterology
55 results on '"Chang Wook, Kim"'

Search Results

1. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

2. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation

3. Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding

4. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

5. Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real‐life settings

6. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study

7. The Role of Urinary N-Acetyl-β-d-glucosaminidase in Cirrhotic Patients with Acute Kidney Injury: Multicenter, Prospective Cohort Study

8. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea

9. Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea

10. Long-term Prognosis of Acute-on-Chronic Liver Failure Survivors

11. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients

12. A simplified prognostic model to predict mortality in patients with acute variceal bleeding

13. Validation of prognostic scores to predict short-term mortality in patients with acute-on-chronic liver failure

14. Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5′-UTR of TRIM22

15. Assessment of scoring systems for acute-on-chronic liver failure at predicting short-term mortality in patients with alcoholic hepatitis

16. On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients

17. Transplantation with autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial

18. A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy

19. Complications Requiring Hospital Admission and Causes of In-Hospital Death over Time in Alcoholic and Nonalcoholic Cirrhosis Patients

20. Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study

21. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection

22. Cholangiocarcinoma with a paraneoplastic leukemoid reaction mimicking a pyogenic liver abscess

23. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial

25. Emergencies in Patients with Hepatocellular Carcinoma

27. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease

28. Long-term prognosis following acute-on-chronic liver failure

29. The best candidates for transarterial chemotherapy in patients with hepatocellular carcinoma awaiting liver transplantation: a cohort-based characterization of dropout times

30. Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study

31. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses

32. Ribonucleotide reductase subunit M2 can be new molecular target and prognostic biomarker of hepatocellular carcinoma

33. Do We Need to Change the Treatment Strategy for Spontaneous Bacterial Peritonitis in Patients with Advanced Cirrhosis?

35. Can 'healthy' normal alanine aminotransferase levels identify the metabolically obese phenotype? Findings from the Korea national health and nutrition examination survey 2008-2010

36. Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A

38. Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis

39. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial

40. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin

41. Benefit of downsizing hepatocellular carcinoma in a liver transplant population

42. Pre- and post-treatment predictors of the early achievement of HBeAg loss in lamivudine-resistant patients receiving adefovir therapy

43. Correlation of hepatitis B core antigen and beta-catenin expression on hepatocytes in chronic hepatitis B virus infection: relevance to the severity of liver damage and viral replication

44. P1100 : Scoring systems proposed for acute-on-chronic liver failure accurately predict short-term mortality in patients with alcoholic hepatitis

45. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization

46. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management

47. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion

48. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma

49. 363 FREQUENT REACTIVATION OF HEPATITIS B VIRUS AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING INTENSIVE TRANSARTERIAL THERAPY: A PROSPECTIVE COMPARISON ANALYSIS

50. 393 ISCHEMIA MODIFIED ALBUMIN AS A EARLY PREDICTOR OF TREATMENT RESPONSE AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Catalog

Books, media, physical & digital resources